Pharsight

1. Brisdelle patents expiration

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US8658663	January, 2012	Decision	Patricia Allison Tewes Richards

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7598271	SEBELA IRELAND LTD	Crystalline paroxetine methane sulfonate	May, 2025 (1 year, 7 months from now)
US8946251	SEBELA IRELAND LTD	Method of treating thermoregulatory dysfunction with paroxetine	Aug, 2026 (2 years from now)
US8658663	SEBELA IRELAND LTD	Method of treating thermoregulatory disfunction with paroxetine	Apr, 2029 (5 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9393237	SEBELA IRELAND LTD	Method of treating thermoregulatory dysfunction with paroxetine	Aug, 2026 (2 years from now)

Market Authorisation Date: 28 June, 2013

Treatment: Treatment of moderate to severe vasomotor symptoms associated with menopause

Dosage: CAPSULE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
7.5 mg	07 Apr, 2014	1	13 Mar, 2019	06 Apr, 2029	Extinguished

Strength	Dosage	Availability
EQ 7.5MG BASE	CAPSULE;ORAL	Prescription

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10166206	SEBELA IRELAND LTD	Topical compositions and methods for making and using same	Jan, 2033 (9 years from now)
US10166205	SEBELA IRELAND LTD	Topical compositions and methods for making and using same	Jan, 2033 (9 years from now)
US10729667	SEBELA IRELAND LTD	Topical compositions and methods for making and using same	Jan, 2033 (9 years from now)
US10695303	SEBELA IRELAND LTD	Topical compositions and methods for making and using same	Jan, 2033 (9 years from now)
US9161914	SEBELA IRELAND LTD	Topical compositions and methods for making and using same	Jan, 2033 (9 years from now)
US8778365	SEBELA IRELAND LTD	Topical compositions and methods for making and using same	Jan, 2033 (9 years from now)

Market Authorisation Date: 27 June, 2013

Treatment: Treatment of fungal infections

Dosage: GEL;TOPICAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.02	04 Feb, 2015	1	10 Apr, 2019	31 Jan, 2033	Deferred

Strength	Dosage	Availability
2%	GEL;TOPICAL	Prescription

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8486456	SEBELA IRELAND LTD	Itraconazole compositions with improved bioavailability	Oct, 2028 (5 years from now)

Market Authorisation Date: 29 April, 2010

Treatment: Onychomycosis of the toenail caused by tricophyton rubrum or trichophyton mentagrophytes, once daily use for 12 consecutive weeks

Dosage: TABLET;ORAL

Strength	Dosage	Availability
200MG	TABLET;ORAL	Discontinued

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7598271	SEBELA IRELAND LTD	Crystalline paroxetine methane sulfonate	May, 2025 (1 year, 7 months from now)